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Abstract
Using selected conditions, the appropriate collagenase, albumin and cell treatment, a preparation of isolated adipocytes
was developed with no extracellular insulin degrading activity. Cell mediated insulin degradation rates were 0.68%"
 .0.05%r100 000 cellrh using trichloracetic acid precipitability as a measure. Chloroquine CQ increased cell-associated
 .  .radioactivity and decreased degradation while dansylcadaverine DC , PCMBS and bacitracin BAC decreased degradation
with no effect on binding. Extraction and chromatography of the cell-associated radioactivity showed 3 peaks, a large
molecular weight peak, a small molecular weight peak and an insulin-sized peak. CQ, DC and BAC all decreased the small
molecular weight peak while CQ and DC also increased the peak of large molecular weight radioactivity. Cell mediated
insulin degradation in the presence of combinations of inhibitors suggested two pathways in adipocytes, one affected by
 .  .inhibitors of the insulin degrading enzyme IDE bacitracin and PCMBS and the other altered by cell processing inhibitors
 .DC, CQ and phenylarsenoxide . Chloroquine altered the pattern of the insulin-sized cell-associated HPLC assayed
degradation products, further supporting two pathways of degradation; one a chloroquine-sensitive and one a chloroquine-
insensitive pathway. q 1997 Elsevier Science B.V.
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1. Introduction
Cellular insulin processing and degradation is a
w xcomplex series of events 1 . The major pathway
involves internalization of receptor bound insulin into
endosomes. Degradation is initiated in these vesicles
 . w xby the insulin degrading enzyme IDE, insulysin 2
prior to acidification of the vesicle and dissociation
w xof the receptor-insulin complex 3 . Initial degrada-
tion by IDE is probably subsequently finished in
lysosomes. However, less than half of the insulin is
) Corresponding author. Fax: q1 402 5596788.
degraded by this process with the remainder translo-
w xcated to other compartments 4 . Some insulin is
released from the cell intact retroendocytosis or dia-
. w xcytosis 5 . Intact insulin remaining in acidic vesicles
may also be degraded by a recently discovered en-
w xzyme 6 . The remainder of the internalized insulin is
available for translocation to the cytosol, nucleus, or
w xother sites 4 . The multiple intracellular locations of
insulin have raised the possibility of an intracellular
action of insulin. In support of this we have shown
direct effects of insulin on the proteasome, the major
w xcytosolic protein degrading complex 7 .
An understanding of potential intracellular insulin
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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action requires additional information on cellular in-
sulin processing. This is particularly true in the
adipocyte in which at least two pathways for insulin
w xtrafficking have been described 8 . One problem
involved in examining cellular pathways for degrada-
tion of insulin is that isolated cells typically leak
degrading activity into the incubation medium and
thus differentiation between extracellular and intra-
cellular degradation is difficult. Degrading activity in
w xthe cell medium can affect hormone action 9 . Pri-
mary culture of hepatocytes has been used to mini-
mize leakage of degrading enzymes into the medium
w x10 . Another approach has been to add inhibitors of
degradation, such as bacitracin, to the incubation
media. Bacitracin, however, alters cellular processing
w xof insulin 11–13 .
To avoid these problems we have established a fat
cell system using carefully controlled preparation and
incubation conditions in which very little extracellu-
lar degradation occurs. With this system we have
examined insulin degradation by this cell type using
inhibitors of the various processes involved. Chloro-
w xquine prevents acidification of endosomes 14 and
thereby blocks subsequent steps in intracellular in-
sulin delivery. Dansylcadaverine acts by an unknown
mechanism to prevent receptor mediated internaliza-
w xtion of insulin 15 . Phenylarsenoxide also inhibits
w xinternalization 16 . Bacitracin and para-chloro-
mercuribenzene sulfonate inhibit insulin degrading
enzyme, competitively and by covalent modification,
respectively. Alone and in combination, these in-
hibitors allow us to dissect out different components
of cellular processing. The present data support the
concept of multiple pathways for insulin degradation
in adipocytes.
2. Materials and methods
2.1. Materials
Reagent grade chemicals were used in all experi-
 .ments. Bovine serum albumin BSA , fraction V, lot
341 was purchased from Miles Laboratories, Elkhart,
w xIN and dialyzed as described previously 17 . Crude
 .bacterial collagenase Type I, Lot 40P080 was ob-
tained from Millipore Corporation, Freehold, NJ. The
w125 xI -iodoinsulin, specifically labeled on the A-14
w xposition 18 , SA 300–350 mCirmg, was a kind gift
from Dr. Bruce Frank, Eli Lilly, Indianapolis, IN.
Chloroquine, bacitracin, para-chloromercuribenzene
 .sulfonate PCMBS and dansylcadaverine were ob-
tained from Sigma Chemical Co., St. Louis, MO.
2.2. Preparation of isolated fat cells
w xCells were prepared by a modification 19 of the
w xmethod of Rodbell 20 . Collagenase digestion was
performed at 378C for 50 min with a concentration of
2.0 mgrml collagenase. All incubations were in
 . w xKrebs–Ringer–Hepes KRH buffer 21 , pH 7.4,
with 4% BSA unless otherwise specified. Numerous
lots of collagenase were tested to find one which
isolated cells without degrading activity in the
medium. The different lots varied widely in the
amount of degrading activity they generated in the
media, with some responsible for as much as 25% of
the total insulin degraded. Cells prepared with the
selected lot of collagenase bound and degraded
w125 xI -iodoinsulin and responded to insulin by increas-
ing glucose utilization, but medium removed from the
incubated cells had negligible degrading activity. The
standard incubation system included 4% BSA which
was necessary to maintain low levels of extracellular
w xdegrading activity 22 .
Fat cell homogenates were prepared by either ho-
mogenization in a glass-on-glass homogenizer, or by
sonication with three second intervals. The ho-
mogenate was centrifuged at 2000=g for 10 min
and the infranatant used for assay. Comparable re-
sults were obtained by either method of cell disrup-
tion.
2.3. Insulin binding and degradation
w125 xIsolated fat cells were incubated with I -A-14-
 y11 .iodoinsulin 2=10 M at 378C for varying times
and binding and degradation determined as described
w x23 . At the indicated times triplicate 300 ml aliquots
were removed and added to microfuge tubes contain-
ing 100 ml dinonyl phthalate. After centrifugation for
1 min in a microfuge, the tubes were cut through the
oil layer and the cell float counted in a gamma
counter for determination of binding. In these studies,
the term ‘binding’ is used to indicate cell-associated
radioactivity. At 378C, not all of the cell-associated
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radioactivity is located on receptors and, thus, the
term ‘binding’ includes internalized as well as mem-
brane-bound material. Nonspecific binding was deter-
mined by adding 1=10y6 M unlabeled insulin and
w125 xsubtracted from binding of tracer I -iodoinsulin to
w125 xyield specific binding. Degradation of the I -
iodoinsulin was assayed by adding the buffer layer
from the microfuge tube to ice-cold KRH buffer
 .followed by sufficient trichloroacetic acid TCA to
give a final concentration of 5%.
2.4. Determination of degrading acti˝ity in the
medium
Cells and media were separated by centrifugation
at 110=g for 60 s. To measure degradation by the
media the infranatant was removed and labeled in-
sulin added for an additional 60 min at 378C. Degra-
dation was assayed as described above. No detectable
extracellular degradation was found in any of these
experiments. With this procedure, the total insulin
degrading activity of adipocytes averaged 0.68%"
0.05%r100 000 cellrh mean"SEM of nine experi-
.ments in triplicate.
2.5. Column chromatography
w125 xAfter incubation with I -A-14-iodoinsulin, the
cells were extracted with 1 M acetic acid, 0.1%
Triton X-100 and 4 M urea. The extracted material
was chromatographed on a 0.9=55 cm Sephadex
G-50 column equilibrated with 1 M acetic acid. The
radioactivity eluted in three peaks as described previ-
w xously 24 with peak 1 corresponding to the void
volume, or large molecular weight material, peak 2 to
the exclusion volume of insulin and peak 3 to small
molecular weight material.
2.6. HPLC
The lyophilized ‘insulin-sized’ material from the
Sephadex G-50 step was dissolved in 0.2 M ammo-
nium phosphate, pH 4.0 and 250 ml 50–100 000
.cpm was applied to a reversed-phase, high perfor-
 .mance liquid chromatography HPLC column. The
HPLC system was a modification of a previously
w xpublished method 25 and consisted of a DuPont
Zorbax C-8 column 4.6 mm=25 cm; 6 mm particle
.diameter maintained at 408C. Samples were eluted
with a bufferracetonitrile system by a series of iso-
cratic and gradient steps in which the acetonitrile
 .concentration was increased from 23.75% vrv to
40% over a 100 min period. The buffer component of
the elution solvents was 0.2 M ammonium phosphate,
pH 4.0, for all steps. One-half milliliter fractions
were collected and were counted in a Tracor Analytic
1285 gamma counter at an efficiency of 85%. Recov-
ery of radioactive materials from the HPLC column
was 95–100% and the sample applied to the HPLC
w xcolumn was 2–3% TCA soluble 25 .
3. Results
The effect of selected inhibitors on insulin binding
and degradation was examined using this system. The
results of these studies are shown in Table 1. Cell
associated radioactivity was increased by all of the
Table 1
w125 xThe effect of various agents on binding and degradation of I -iodoinsulin to adipocytes
Binding Degradation
45 min 90 min 45 min 90 min
Control 1.29"0.09 1.51"0.17 2.16"0.13 5.11"0.41
aqDansylcadaverine 1.95"0.04 1.82"0.16 2.02"0.20 4.80"0.51
bqChloroquine 2.80"0.45 3.55"0.41 1.34"0.30 2.95"0.30
bqBacitracin 1.73"0.15 1.66"0.21 1.28"0.35 2.73"0.35
bqPCMBS 1.46"0.14 1.41"0.10 0.46"0.07 0.98"0.09
 .Adipocyte concentration was 400 000rml. Values are percent of total radiolabeled insulin that is cell associated mean"SEM .
a 0.2 mM.
b 0.5 mM.
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inhibitors although only chloroquine was significant
 .P-0.01 . Similarly all of the agents inhibited
degradation although dansylcadaverine, an inhibitor
of internalization, had no significant effect. Chloro-
quine, an inhibitor of intracellular processing, pro-
 .duced a 40% decrease in degradation P-0.05 .
PCMBS and bacitracin, inhibitors of the insulin de-
grading enzyme, decreased degradation with PCMBS
 . having the greatest effect 80% inhibition all with
.P-0.05 .
The effects of the various agents on insulin degra-
dation by fat cell homogenates were also examined
 .data not shown . Bacitracin and PCMBS signifi-
cantly inhibited degradation by cell homogenates,
but, as expected, chloroquine and dansylcadaverine
did not alter degradation by broken cells.
The nature of the cell associated radioactivity in
the presence and absence of these various agents was
examined by molecular sieve chromatography. Fat
 6 .cells 1.2 = 10 cellsrml were incubated with
w125 xI -iodoinsulin with and without the various in-
hibitors. After extraction and molecular sieve chro-
matography, the distribution of labeled material was
 .determined. Chloroquine increased binding Table 2 ,
while dansylcadaverine and bacitracin had no effect
at these concentrations. Because of the high cell
concentration, total degradation was greater than that
in earlier experiments, but, expressed per 100 000
 .cells, was typical 0.6%r100 000 cellrh . All of the
agents decreased degradation as reflected by de-
w125 xcreased TCA solubility of the I -iodolabeled mate-
rial in the incubation medium and by a decrease in
the small molecular weight material in the cell ex-
tract. Chloroquine and dansylcadaverine increased the
absolute and relative amount of labeled material in
w125 xFig. 1. The effects of combinations of inhibitors on I -
iodoinsulin binding and degradation by adipocytes. Inhibitor
concentrations and incubation conditions were as in Table 1.
the large molecular weight peak, suggesting an alter-
ation in the processing of this component of the cell
associated material.
Because none of the inhibitors totally blocked
degradation and because of evidence of more than
w xone pathway for insulin degradation by cells 8 ,
combinations of inhibitors were examined. Chloro-
quine and bacitracin together increased binding Fig.
.1 . PCMBS partially blocked the chloroquine related
increase in binding. Dansylcadaverine plus bacitracin
and PCMBS plus bacitracin had no significant effect
on binding.
Chloroquine plus bacitracin inhibited degradation
 .better than either alone Fig. 1 and PCMBS plus
chloroquine totally inhibited cellular degradation.
Table 2
The effect of various agents on cell associated radioactivity
 .  .Total degradation % Total cell associated Distribution of cell associated radioactivity %
 .radioactivity % peak 1 peak 2 peak 3
Control 7.2 1.8 6.7"1.2 80"1.2 11.7"2.0
Chloroquine, 0.5 mM 4.1 3.4 11.3"1.4 88.7"0.9 0"0.0
Dansylcadaverine, 0.5 mM 6.5 2.0 12.3"1.3 84"1.1 3.7"0.3
Bacitracin, 0.2 mM 4.1 1.7 6.0"0.6 90.0"1.1 3.7"0.7
 6 .Adipocytes approximately 1.2=10 cellsrml were incubated as described in Section 2 for 60 min, centrifuged through dinonyl
phthalate and the cell pellet extracted and chromatographed on Sephadex G-50, as described in the text. Results shown are mean"SEM
of three experiments.
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Dansylcadaverine plus bacitracin was more effective
than either alone. Thus, the combination of an en-
 .zyme inhibitor bacitracin or PCMBS and an in-
hibitor of cellular processing chloroquine or dansyl-
.cadaverine was additive. In contrast, two enzyme
inhibitors were not better than PCMBS alone. Taken
together these data suggest two pathways for insulin
degradation, by adipocytes. One pathway involves
internalization and intracellular degradation, suscepti-
ble to agents such as chloroquine and dansylcadaver-
ine which block these pathways. The other pathway
is inhibited by inhibitors of the insulin degrading
enzyme.
To confirm these conclusions, three additional ex-
periments were done with chloroquine and bacitracin
alone and in combination. Chloroquine again in-
 .creased binding 215"32% of control and de-
 .creased degradation 33"12% . Bacitracin produced
 .a slight increase in binding 126"12% and de-
 .crease in degradation 36"5% . With the combina-
tion binding was 152"22% of control and degrada-
tion was decreased to 67"6% P-0.05 as com-
.pared with either alone .
To examine this further, phenylarsenoxide, another
w x inhibitor internalization 16 , was examined Table
.3 . This agent inhibited internalization, as reflected
by the acid wash technique. In the presence of pheny-
Fig. 2. The effects of chloroquine and phenylarsenoxide on
w125 xI -iodoinsulin binding and degradation by adipocytes. Chloro-
quine concentration was 0.2 mM and phenylarsenoxide concen-
tration was 1 mM. The adipocyte concentration was 250000rml.
Table 3
Effect of phenylarsenoxide on insulin internalization by
adipocytes
Condition Specifically Bound after Internalized
 .  .bound % acid wash %
 .%
158C 1.46 0.26 17
378C 1.13 0.49 43
378Cqphenylarsen- 0.73 0.12 17
 .oxide 1 mm
w125 x  y11 .Adipocytes were incubated with I -iodoinsulin 1=10 M
for 60 min and aliquots taken for determination of specific
binding as described in Section 2. Additional aliquots were taken
 .and acetic added final pH 3.5 . After 5 min incubation, binding
was determined.
larsenoxide 83% of the cell associated radioactivity
was displaced by acid which is the same as the
 .control incubation at 158 . Without phenylarsenoxide
approximately 43% of cell associated radioactivity
was internalized, in agreement with other studies
w x26 . The combined effects of phenylarsenoxide and
chloroquine on insulin binding and degradation by
adipocytes is shown in Fig. 2. Phenylarsenoxide
blocked the chloroquine induced increase in binding.
Chloroquine, phenylarsenoxide, and the combination
of the two agents had similar inhibitory effects on
adipocyte insulin degradation suggesting that both
were active against the same pathway.
These studies strongly support the presence of two
pathways for insulin degradation in adipocytes. Mul-
tiple effects of inhibitors are common and solubility
in TCA as the index of insulin degradation may at
times be misleading. We therefore used a different
approach for the examination of cell-mediated insulin
w125 xdegradation in adipocytes. I -A-14-iodoinsulin was
incubated with adipocytes and the cells washed, ex-
tracted and the extracted material chromatographed
on Sephadex G-50. The insulin-sized peak was ana-
 .lyzed by reversed-phase HPLC Fig. 3, panel A . As
can be seen, several insulin-sized materials elute
differently from HPLC demonstrating that adipocytes,
as hepatocytes, contain insulin-sized degradation
products. Similar studies were done with adipocytes
 .incubated with chloroquine Fig. 3, panel B . The
elution pattern shows differences in insulin-sized
degradation products in chloroquine-treated cells,
( )W.C. Duckworth et al.rBiochimica et Biophysica Acta 1358 1997 163–171168
w125 xFig. 3. HPLC elution pattern of ‘insulin-sized’ labeled material associated with the cell. Fat cells incubated with I -iodoinsulin were
extracted and the extract chromatographed on a G-50 Sephadex column. The ‘insulin’ peak was injected on a reversed-phase HPLC and
the elution pattern shown. Panel A control cells, Panel B chloroquine treated cells.
confirming that chloroquine alters cellular metabolism
of insulin. Insulin-sized degradation products are pre-
sent in chloroquine-treated cells, further supporting
the conclusion that there are chloroquine sensitive
and chloroquine insensitive pathways for insulin
degradation in isolated adipocytes.
4. Discussion
The interaction of insulin with cells is complex.
The initial step is binding to a specific membrane
receptor which results in the biological responses and
is the first step in the ‘processing’ of the hormone,
which includes internalization and degradation of the
w xhormone receptor complex 1 . The cellular mecha-
nisms for insulin metabolism remain uncertain. Many
different approaches have been used in attempts to
understand insulin-cell interactions, including the use
of inhibitors of various steps in processing. Chloro-
quine increases cell-associated radioactivity of
w125 x w xadipocytes incubated with I -iodoinsulin 27 . This
has been interpreted to support a lysosomal involve-
ment in insulin processing, although chloroquine al-
w xters prelysosomal processing 14 . It has, however,
been difficult to demonstrate a major effect of chloro-
quine on insulin degradation by the adipocyte. Ham-
mons and Jarett, for example, found that chloroquine
w xdecreased degradation only from 21.1 to 18.5% 28 .
Marshall and Olefsky also found only a slight de-
crease in insulin degradation by adipocytes exposed
to chloroquine in spite of a large increase in cell
w xbound radioactive material 27 . Much of the diffi-
culty in demonstrating a major effect of chloroquine
on adipocytes has been due to significant amounts of
degrading activity in the medium.
The current study shows that an adipocyte prepara-
tion can be obtained with minimal extracellular de-
grading activity and low total insulin degradation.
Considerable care in the selection of collagenase and
albumin was required. Even minimal cellular damage
can result in release of degrading activity into the
medium. Additionally, contaminants in the collage-
nase preparation contribute to insulin degradation
w x29 . Albumin is necessary for inhibition of residual
w xextracellular degrading activity 22 . It is also neces-
sary to use a labeled hormone as nearly identical to
the native hormone as possible, specifically insulin
w xlabeled on the A-14 tyrosine 23 .
With this system we have shown that the chloro-
quine-sensitive pathway is a significant pathway for
w xinsulin degradation in the fat cell 30 . Total insulin
degradation was decreased one-third to one-half by
the addition of 0.5 mM chloroquine. No additional
effect was seen by increasing the chloroquine concen-
 .tration up to 2 mM data not shown . A major
component of adipocyte degradation is not chloro-
quine-sensitive, suggesting additional pathways for
insulin metabolism. Previous studies also concluded
that only a portion of insulin degradation in adipocytes
w xwas chloroquine-sensitive 31,32 , as in hepatocytes
w x33,34 .
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To examine other possible pathways, inhibitors
with different effects on insulin degradation were
examined. Bacitracin and PCMBS inhibit the insulin
w xdegrading enzyme 1 and decreased insulin degrada-
tion by both intact cells and homogenates, supporting
a role for IDE. However, neither agent completely
suppressed degradation, suggesting some degradation
occurs that is not mediated by IDE. Bacitracin did not
increase the amount of high molecular weight ra-
dioactivity found in the cells, whereas chloroquine
and dansylcadaverine did. We have evidence unpub-
.lished data that indicates the high molecular weight
material is a fibril made of partially cleaved insulin
crosslinked by disulfide bonds either to itself or other
proteins. Chloroquine and dansylcadaverine appear to
inhibit insulin processing at a step after its initial
 .cleavage s , thereby allowing more time for the par-
tially degraded hormone to form mixed disulfides.
The function of and mechanism by which this insulin
degraded product is cleared from the cell are not
known.
Dansylcadaverine, chloroquine and phenylarsenox-
ide are inhibitors of cellular processing of receptor
w xbound ligands 34,35 and all partially blocked insulin
degradation. In a previous study with hepatocytes, we
demonstrated that dansylcadaverine and chloroquine
affected the same pathway of insulin metabolism
w x35 . The present data support that concept since
dansylcadaverine and chloroquine were not additive
in their effect. Neither was the combination of
chloroquine and phenylarsenoxide. Dansylcadaverine
and phenylarsenoxide blocked the chloroquine-in-
duced increase in cell associated radioactivity, sup-
porting the concept that dansylcadaverine and pheny-
larsenoxide act on a step preceding the chloroquine
effect and all are active on the same cellular pathway.
Studies of the cellular degradation products of insulin
also support a chloroquine-sensitive and a chloro-
quine-insensitive pathway for insulin degradation.
Cell-associated insulin-sized material in hepatocytes
includes intact insulin and several degradation prod-
w xucts 12 . The most prominent of the insulin-sized
products is a doublet which elutes from HPLC prior
to intact insulin. In adipocytes, we demonstrate a
similar doublet and another product which elutes
before insulin. The addition of chloroquine to cells
eliminates the doublet in adipocytes, as in hepato-
w xcytes 35 , with little or no effect on the other prod-
uct. This further supports the concept of two path-
ways for insulin degradation in adipocytes.
These findings may have relevance to the actions
of insulin in adipocytes as it does in hepatocytes.
Inhibitors of internalization such as dansylcadaverine
and methylamine block some of the intermediate
term actions of insulin, i.e. actions which require
minutes to hours of insulin exposure. The effects of
insulin on protein degradation and alanine transport
in liver are totally blocked by dansylcadaverine and
w xmethylamine 36,37 . This is a specific effect on
insulin action since amino acid inhibition of protein
degradation is not altered by these inhibitors. A short
term effect of insulin, stimulation of glycogen synthe-
w xsis, is unaffected by this treatment 36,37 .
Much has been learned about the mechanism of
 .insulin action on short-term e.g. glucose transport
 .and long-term e.g. mitogenesis effects. It is now
clear that different signal transduction systems are
involved in the generation of these effects. In con-
trast, little attention has been given to intermediate-
term effects, such as inhibition of protein degrada-
tion.
Recent studies from our laboratory have suggested
a potential mechanism for insulin control of protein
turnover. Insulin has a direct inhibitory effect on
w xproteasomes 7 , the major cytoplasmic degradative
complex and the target of insulin’s inhibition of
w xprotein degradation 38 . We have hypothesized that
internalized insulin is delivered to the cytosol where
w xit interacts with IDE 39 . IDE forms a complex with
w xthe proteasome 40 and the insulin-IDE interaction
results in inhibition of the proteolytic activity of the
proteasome. Cytosolic IDE, thus, has a regulatory
function on proteasome activity. This mechanism
would explain the blocking by internalization in-
hibitors, such as dansylcadaverine, of the insulin
effect on protein degradation.
The regulatory role of IDE on proteasomes is not
unique. IDE also associates with other cytosolic com-
plexes, the androgen and glucocorticoid receptors and
w xregulate their activity 41,42 . IDE increases steroid
receptor binding to DNA, an effect reversed by in-
sulin interaction with the IDE-steroid receptor com-
plex. These data suggest that at least two intermediate
actions of insulin, inhibition of protein degradation
and alteration of steroid hormone effects, may be due
to intracellular insulin-IDE interaction.
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Investigation of this potential mechanism of in-
sulin action will require additional understanding of
the pathways of cellular insulin processing. Not all
inhibitors of intracellular processing block insulin
action. Chloroquine does not prevent insulin inhibi-
tion of protein degradation, neither in isolated cells
w x w x36,37 nor in the whole animal 38 .
The present study suggests that dansylcadaverine
and chloroquine work on the same pathway but
chloroquine acts at a later step. If this interpretation is
correct, then intracellular insulin action, i.e. delivery
of insulin to cytosol, occurs after internalization
 .blocked by dansylcadaverine and prior to acidifica-
 .tion of the endosome blocked by chloroquine . Pre-
vious studies have shown that internalized insulin
interacts with IDE in the endosome prior to acidifica-
w xtion of the vesicle 3 , generating the characteristic
w xintracellular products of insulin degradation 2 .
Taken together, previous studies and the data from
the present study support the following hypothesis.
Receptor bound insulin is internalized into endo-
somes. Prior to acidification of the endosome, insulin
interacts with IDE, either within the endosome or in
cytosol. Insulin–IDE interaction may result in degra-
dation of the insulin or mediate some of the interme-
 .diate term actions of insulin or both . After endoso-
mal acidification, insulin no longer reacts with IDE
and is processed and degraded by different mecha-
nisms, possibly by an acidic endosomal proteinase
w x6 . While speculative, this hypothesis is supported by
the available data, including those in the present
paper. Acceptance or rejection of this hypothesis will
require additional information on cellular insulin pro-
cessing and the intermediate actions of insulin.
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